TAM (Treatments and Medicines) NHS Highland
Important: Therapy notes
Abiraterone is included in the Highland Formulary for use with prednisolone for the treatment of metastatic castration-resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen:
- in accordance with the SMC 764/12 restriction for use in patients who have received only one prior chemotherapy regimen
- the small cohort of patients in NHS Highland who have received second-line chemotherapy since abiraterone received its UK marketing authorisation
- in patients who have received only one prior chemotherapy regimen in the castrate refractory period but have received chemotherapy in the castrate sensitive phase within a clinical trial.
Important: Formulation and dosage details
Formulation:
Tablets 500mg (specialist use only)
Dosage:
1 gram once daily.
As per SMC 764/12: with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
SMC restriction: abiraterone is restricted to use in patients who have received only one prior chemotherapy regimen.
873/13: abiraterone acetate is indicated with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.
2215: abiraterone acetate with prednisone or prednisolone for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer in adult men in combination with androgen deprivation therapy.